MedPath

Efficacy and safety of hydroxychloroquine for Japanese patients with rheumatoid arthritis

Phase 2
Conditions
rheumatoid arthritis
Registration Number
JPRN-UMIN000023989
Lead Sponsor
Division of Rheumatology, Keio University School of Medicine
Brief Summary

The addition of HCQ to csDMARDs was effective, with no new safety signal in patients with RA.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

1) Pregnancy or hope to bear a child 2) Contraindication to HCQ, e.g. history of retinopathy and hypersensitivity to 4-aminoquinoline 3) Uncontrollable diabetes mellitus 4) Porphyria 5) Psoriasis 6) G6PD deficiency 7) Ineligible for the study judged by physicians

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath